Analysts forecast that Tandem Diabetes Care Inc (NASDAQ:TNDM) will report earnings per share of ($1.28) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Tandem Diabetes Care’s earnings, with the lowest EPS estimate coming in at ($1.37) and the highest estimate coming in at ($1.19). Tandem Diabetes Care posted earnings of ($4.80) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 73.3%. The firm is scheduled to report its next earnings report after the market closes on Thursday, March 1st.
According to Zacks, analysts expect that Tandem Diabetes Care will report full year earnings of ($15.15) per share for the current fiscal year, with EPS estimates ranging from ($16.99) to ($13.31). For the next financial year, analysts expect that the business will report earnings of ($4.97) per share, with EPS estimates ranging from ($6.15) to ($2.87). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Tandem Diabetes Care.
Several analysts recently commented on TNDM shares. Zacks Investment Research downgraded Tandem Diabetes Care from a “buy” rating to a “hold” rating in a research note on Tuesday, October 17th. Robert W. Baird reaffirmed a “hold” rating and set a $3.00 price objective on shares of Tandem Diabetes Care in a research note on Sunday, November 19th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $11.29.
In other news, CEO Kim D. Blickenstaff purchased 750,000 shares of the company’s stock in a transaction on Friday, February 9th. The shares were purchased at an average price of $2.00 per share, with a total value of $1,500,000.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Christopher J. Twomey purchased 75,000 shares of the company’s stock in a transaction on Friday, February 9th. The stock was purchased at an average cost of $2.00 per share, for a total transaction of $150,000.00. The disclosure for this purchase can be found here. Company insiders own 20.90% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in shares of Tandem Diabetes Care by 2.7% in the 2nd quarter. Vanguard Group Inc. now owns 1,233,607 shares of the medical device company’s stock valued at $987,000 after purchasing an additional 32,991 shares during the period. Russell Investments Group Ltd. raised its stake in shares of Tandem Diabetes Care by 13.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 659,993 shares of the medical device company’s stock valued at $482,000 after purchasing an additional 78,748 shares during the period. Finally, Wedbush Securities Inc. raised its stake in shares of Tandem Diabetes Care by 88.6% in the 3rd quarter. Wedbush Securities Inc. now owns 188,877 shares of the medical device company’s stock valued at $138,000 after purchasing an additional 88,709 shares during the period.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.